Patient Leaflet Updated 11-Nov-2024 | Gilead Sciences Ltd
Sunlenca 464 mg solution for injection
Sunlenca 464 mg solution for injection
lenacapavir
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Sunlenca is and what it is used for
2. What you need to know before you are given Sunlenca
3. How Sunlenca is given
4. Possible side effects
5. How to store Sunlenca
6. Contents of the pack and other information
Sunlenca contains the active substance lenacapavir. This is an antiretroviral medicine known as a capsid inhibitor.
Sunlenca is a long acting medicine and is used in combination with other antiretroviral medicines to treat type 1 human immunodeficiency virus (HIV), the virus that cause acquired immunodeficiency syndrome (AIDS).
It is used to treat HIV infection in adults with limited treatment options (for example when other antiretroviral medicines are not sufficiently effective or are not suitable).
Treatment with Sunlenca in combination with other antiretrovirals reduces the amount of HIV in your body. This will improve the function of your immune system (the body’s natural defences) and reduce the risk of developing illnesses linked to HIV infection.
Talk to your doctor before using Sunlenca
Once you start using Sunlenca, look out for:
It is important that you attend your planned appointments to receive your Sunlenca injection, to control your HIV infection, and to stop your illness from getting worse. Talk to your doctor if you are thinking about stopping treatment. If you are late receiving your Sunlenca injection, or if you stop receiving Sunlenca, your will need to take other medicines to treat your HIV infection and to reduce the risk of developing viral resistance.
Do not give this medicine to children under 18 years of age. The use of Sunlenca in patients aged under 18 has not yet been studied, so it is not known how safe and effective the medicine is in that age group.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Sunlenca may interact with other medicines. This may keep Sunlenca or other medicines from working properly, or may make side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.
Medicines that must never be taken with Sunlenca:
Talk to your doctor in particular if you are taking:
Sunlenca is a long-acting medicine. If after talking to your doctor you decide to stop your treatment or switch to another, you should know low levels of lenacapavir (the active substance in Sunlenca) can remain in your system for many months after your last injection. These low remaining levels should not affect other antiretroviral medicines that you take afterwards to treat your HIV infection. Some other medicines however may be affected by the low levels of lenacapavir in your system if you take them within 9 months after your last Sunlenca injection. You should check with your doctor if such medicines are safe for you to take after you stop treatment with Sunlenca.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
As a precautionary measure you should avoid the use of Sunlenca during pregnancy unless your doctor tells you otherwise.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby through breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Sunlenca is not expected to have any effect on your ability to drive or use machines.
This medicine contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially ‘sodium-free’.
Sunlenca is used in combination with other antiretroviral medicines to treat HIV infection. Your doctor will advise which other medicines you need to take to treat your HIV infection, and when you need to take them.
Your treatment with Sunlenca starts with tablets you take by mouth, followed by injections given by your doctor or nurse, as described below.
Talk to your doctor before taking the tablets. You will be advised when to start your tablets and when your appointment for the first injections will be scheduled.
Day 1 of treatment:
Day 2 of treatment:
Day 8 of treatment:
Day 15 of treatment:
Every 6 months:
Your doctor or a nurse will give this medicine to you, so it is unlikely that you will be given too much. If you are worried, tell the doctor or a nurse.
If you miss or vomit the tablets, refer to the package leaflet for Sunlenca tablets.
Do not stop receiving Sunlenca without talking to your doctor. Keep receiving Sunlenca injections for as long as your doctor recommends. Stopping Sunlenca can seriously affect how future HIV treatments work.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects
(may affect more than 1 in 10 people)
Common side effects
(may affect up to 1 in 10 people)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from light.
The active substance is lenacapavir. Each single-use vial contains 463.5 mg of lenacapavir.
The other ingredients are
Macrogol (E1521), water for injections.
Sunlenca solution for injection (injection) is a clear, yellow to brown solution with no visible particles. Sunlenca comes in two glass vials, each containing 1.5 ml of solution for injection. These vials are included in a dosing kit also containing 2 vial access devices (a device that will allow your doctor or a nurse to withdraw Sunlenca from the vial), 2 disposable syringes and 2 injection needles.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 07/2024.
C8026
280 High Holborn, London, WC1V 7EE, UK
+44 (0)203 681 4681
08000 113 700 (UK)
+44 (0)203 681 4500
+353 1 291 3580 (Ireland)
+353 214 825 999 (Ireland)